A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2015
At a glance
- Drugs Icosabutate (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Pronova BioPharma
- 06 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Nov 2013 New trial record
- 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.